QCG
PBYI icon

Quadrant Capital Group’s Puma Biotechnology PBYI Stock Holding History

Quadrant Capital Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-586
Closed -$2K – 2642
2021
Q4 		$2K Buy
+586
New +$2.54K ﹤0.01% 2163
2016
Q1 		– Sell
-139
Closed -$10K – 1928
2015
Q4 		$10K Buy
139
+58
+72% +$4.55K 0.01% 800
2015
Q3 		$6K Buy
+81
New +$7.66K ﹤0.01% 778

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Quadrant Capital Group's PBYI Position: Q1 2022 in Review

Quadrant Capital Group sold out of Puma Biotechnology (PBYI) in Q1 2022, closing a stake of 586 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in PBYI in Q3 2015 and held it in 3 quarters. The position peaked at $10K in Q4 2015. 104 funds tracked by Wall St. Rank hold PBYI as of Q1 2022.

  • Quadrant Capital Group reported no remaining Puma Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 586 Puma Biotechnology shares in Q1 2022, an estimated $2K.
  • Quadrant Capital Group first reported a position in Puma Biotechnology in Q3 2015 and held it in 3 quarters.
  • Quadrant Capital Group's Puma Biotechnology position peaked at $10K in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.